| DB ID | MyCo_3290 |
| Title | Mould-reactive T cells for the diagnosis of invasive mould infection-A prospective study |
| Year | 2019 |
| PMID | 31034691 |
| Fungal Diseases involved | Invasive mold infection |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | Adult at‐risk patients with haematologic disorder, haematologic ma‐ lignancy or allogeneic HSCT were eligible for participation within the scope of the protocol Improving Diagnosis of Severe Infections of Immunocompromised Patients (ISI, Identifier of the University of Cologne Ethics Committee 08‐160). |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | CD154 |
| Biomarker Full Name | CD154 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Germany |
| Cohort | Adult at‐risk patients with haematologic disorder, haematologic ma‐ lignancy or allogeneic HSCT were eligible for participation within the scope of the protocol Improving Diagnosis of Severe Infections of Immunocompromised Patients (ISI, Identifier of the University of Cologne Ethics Committee 08‐160). Written informed consent was obtained from the patient or legal guardian. Peripheral ethylenedi‐aminetetraacetic acid (EDTA) blood samples at a maximum of 20 ml twice weekly were prospectively collected from 115 patients between December 2014 and November 2016. |
| Cohort No. | 115 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive mould infections (IMI) are a considerable threat for immunocompromised patients, particularly those with haematologic malignancies and allogeneic haematopoietic stem cell transplant (HSCT) recipients.1,2 Despite diagnostic and therapeutic advances, managing IMI remains challenging. Mortality rates of up to 100% in untreated mucormycosis patients3 call for early diagnosis and targeted antifungal treatment. |
| Technique | Analytic |
| Analysis Method | Flow Cytometry Analysis |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Flow Cytometry Analysis |
| Up Regulation Down Regulation | Up regulated |
| Sequence Data | None |
| External Link | None |
